This position is no longer accepting applications
Director, Head of International Communications at CSL Seqirus has been filled or removed.
We'll email you when new Infectious Disease roles in EMEA, GB, Berkshire, Maidenhead, CSL Behring; EMEA, CH, Glattbrugg, CSL Behring are posted.
CSL is looking for a Head of International Communications to lead strategic communications for its Commercial & Medical International business — a $13 billion operation spanning 39 countries and five regions, treating roughly 19 million patients with therapies for haemophilia, hereditary angioedema, and other rare and complex conditions. This is a senior communications leadership role, reporting to the Head of Global Communications, CSL Behring, Vifor and Plasma and serving as the direct communications partner to the SVP of International, with oversight of a team of five.
Hybrid based (3 days a week) from our UK office in Maidenhead, with Switzerland and Germany other potential locations
Why It Matters
CSL holds the leading global position, and much of that position depends on trust — from regulators, from healthcare systems, from the employees and affiliate markets who carry the strategy into 39 different countries. This role sits at the point where business strategy becomes communication: shaping how leadership is understood internally, how the company responds when issues get complicated, and how a genuinely global organisation holds a coherent identity across very different markets. It's a role for someone who sees communications as a strategic function, not a support one.
What You'll Be Responsible For
The role covers the full range of strategic communications for the International Region — from executive counsel to crisis response to the internal narrative that keeps a dispersed organisation aligned. Specifically, you'll:
Experience Required
Note on Travel
Approximately 15% travel, predominantly pan-European.
CSL Seqirus is part of CSL. As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
To learn more about CSL, CSL Behring, CSL Seqirus and CSL Vifor visit https://www.csl.com/ and CSL Plasma at https://www.cslplasma.com/.
Our Benefits
For more information on CSL benefits visit How CSL Supports Your Well-being | CSL.
You Belong at CSL
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out. By celebrating our differences and creating a culture of curiosity and empathy, we are able to better understand and connect with our patients and donors, foster strong relationships with our stakeholders, and sustain a diverse workforce that will move our company and industry into the future.
To learn more about inclusion and belonging visit https://www.csl.com/careers/inclusion-and-belonging
Equal Opportunity Employer
CSL is an Equal Opportunity Employer. If you are an individual with a disability and need a reasonable accommodation for any part of the application process, please visit https://www.csl.com/accessibility-statement.
Watch our ‘On the Front Line’ video to learn more about CSL Seqirus
BIOTECHNOLOGY
Flu vaccine
This listing was originally posted on CSL Seqirus's careers page. Formulate is an equal opportunity job aggregator and is not involved in the hiring process. Where salary information is estimated, it is derived from BLS industry benchmarks and may differ from actual compensation.
Upgrade to Pro to access the AI-generated 'Read before applying' briefing and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo